Analysis of China Resources Double‑Crane Subsidiary Clears FDA for DC7001A Capsules – Investigational Therapy Advances Toward Clinical Trials in Systemic Lupus Erythematosus - aVenture Research
Insight, China's Pharmaceutical Industry
China Resources Double‑Crane Subsidiary Clears FDA for DC7001A Capsules – Investigational Therapy Advances Toward Clinical Trials in Systemic Lupus Erythematosus
China Resources Double‑Crane Pharmaceutical Co., Ltd. (SHA: 600062) announced that its wholly-owned subsidiary, Beijing Double‑Crane Runchuang Technology Co., Ltd., has received notice from the U.S. Food and Drug Administration (FDA) agreeing to the conduct of clinical trials for DC7001A capsules (IND No. 183387) in the United States. The investigational drug is intended for the treatment of systemic lupus erythematosus (SLE) — marking a dual-jurisdiction clinical pathway for the asset, which al